Clinical Trials Logo
  1. Home
  2. Hemoglobinopathies
  3. NCT04029142
  4. Details
NCT04029142 Clinical Trial

Screening for Hemoglobinopathies in Pregnant Women

Hemoglobinopathies Clinical Trial

Official title:
Screening for Hemoglobinopathies in Pregnant Women

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04029142
Other study ID # 2019-01065; sp19Amstad
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 3, 2019
Est. completion date September 30, 2019

Study information
Verified date February 2024
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This prospective monocentric study project is to identify hemoglobinopathies in pregnant women in order to optimize antenatal care and to investigate the prevalence of hemoglobinopathies in pregnant women in Switzerland.

Recruitment information / eligibility
Status Completed
Enrollment 1785
Est. completion date September 30, 2019
Est. primary completion date September 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - pregnant women seen at the Frauenklinik at University Hospital Basel Exclusion Criteria: - pregnant women with already known hemoglobinopathy - refusal of participation

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Review of routine lab data
Review of routine lab data from pregnant women (first trimester)

Locations
Country Name City State
Switzerland Frauenklinik University Hospital Basel Basel

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Amstad Bencaiova G, Geissler F, Hoesli I. Cohort profile: targeted antenatal screening for haemoglobinopathies in Basel. BMJ Open. 2020 Jul 22;10(7):e035735. doi: 10.1136/bmjopen-2019-035735. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary identification of hemoglobinopathies identification of hemoglobinopathies by investigating routine lab samples single time point assessment at baseline
See also
  Status Clinical Trial Phase
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Active, not recruiting NCT03655678 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia Phase 2/Phase 3
Completed NCT03609827 - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Recruiting NCT06107400 - Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease Early Phase 1
Enrolling by invitation NCT02986698 - In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) Phase 1
Completed NCT00744692 - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders Phase 1
Recruiting NCT05799118 - Study of the Role of Genetic Modifiers in Hemoglobinopathies
Active, not recruiting NCT03745287 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease Phase 2/Phase 3
Completed NCT00673608 - Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Phase 4
Recruiting NCT04644016 - Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Phase 2
Recruiting NCT04853576 - A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) Phase 1/Phase 2
Recruiting NCT05356195 - Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) Phase 3
Completed NCT03609840 - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Active, not recruiting NCT01850108 - Non-Myeloablative Conditioning and Bone Marrow Transplantation N/A
Recruiting NCT05329649 - Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) Phase 3
Active, not recruiting NCT01966367 - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT00153985 - Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies Phase 2
Recruiting NCT03128996 - Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders Phase 1/Phase 2
Completed NCT03149289 - Hepatitis C Virus Infection in Patients With Hemoglobinopathies N/A
Completed NCT00000588 - Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone Phase 2